35986841_10216840653711318_1105697261150535680_n
Normal view MARC view ISBD view

Design of novel potential protease inhibitors for the treatment of HIV // GP // Dr. Rana Hosny Refaey (2018 - 2019)

By: Ramla Ahmed Ali 152887.
Contributor(s): Aya Mohamed Ahmed 150869 | Lamiaa Khaled Farouk 150973 | Nada Ibrahim El-Sayed 150131.
Material type: TextTextSeries: Pharmacy distinguished Projects 2019. Publisher: Giza : MSA, 2019Description: 65 p.Subject(s): Human immunodeficiency virus | potential protease | Pharmaceutical ChemistryOnline resources: FULL TEXT PRESS HERE Summary: Human immunodeficiency virus (HIV) is a serious infection that progressively destructs the human immune system. Protease enzyme is a very important enzyme in the life cycle of the HIV and its replication. The Protease inhibitors are classified as one of the important classes in HIV treatment as they decrease the protease enzyme of the HIV. However, they have shown a risk in causing insulin resistance and leading to diabetes mellites due to their high affinity to GLUT4. Consequently, we tried to design novel protease inhibitors that have reduced affinity to GLUT4 and exhibit low incidence of insulin resistance. For such design to be developed, computer-based drug design methods were used. Using MOE program, the protease enzyme was primarily docked in itself for validation and then protease inhibitors were docked in it to observe the energy values and interactions. Then, protease inhibitors were docked in GLUT4 homology model -created on SwissModel- to explore their interactions with it and to identify interactions responsible for binding to GLUT4 causing insulin resistance. For the lead optimization step Darunavir and Ritonavir were chosen. In Darunavir, N38 was changed into C38 and a pentane ring was attached to 018. For Ritonavir, the N5 was changed to $5. These changes lead to significant variation in the affinity of the drugs to both protease enzyme and GLUT4, increasing the affinity to protease enzyme and decreasing it to GLUT4.
List(s) this item appears in: Pharmacy D. G. P 2018 / 2019
Tags from this library: No tags from this library for this title. Log in to add tags.
    Average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Distinguished Graduation Projects Distinguished Graduation Projects Centeral Library
Soft Copy located on library Cataloge
GP38PH2019-Pharm.chem (Browse shelf) Available 82019

Pharmacy - Pharmaceutical Chemistry

Human immunodeficiency virus (HIV) is a serious infection that progressively destructs the human immune system. Protease enzyme is a very important enzyme in the life cycle of the HIV and its replication. The Protease inhibitors are classified as one of the important classes in HIV treatment as they decrease the protease enzyme of the HIV. However, they have shown a risk in causing insulin resistance and leading to diabetes mellites due to their high affinity to GLUT4. Consequently, we tried to design novel protease inhibitors that
have reduced affinity to GLUT4 and exhibit low incidence of insulin resistance. For such
design to be developed, computer-based drug design methods were used. Using MOE program, the protease enzyme was primarily docked in itself for validation and then protease inhibitors were docked in it to observe the energy values and interactions. Then, protease inhibitors were docked in GLUT4 homology model -created on SwissModel- to
explore their interactions with it and to identify interactions responsible for binding to GLUT4 causing insulin resistance. For the lead optimization step Darunavir and Ritonavir were chosen. In Darunavir, N38 was changed into C38 and a pentane ring was attached to 018. For Ritonavir, the N5 was changed to $5. These changes lead to significant variation in the affinity of the drugs to both protease enzyme and GLUT4, increasing the affinity to protease enzyme and decreasing it to GLUT4.

There are no comments for this item.

Log in to your account to post a comment.

Click on an image to view it in the image viewer